| Year |
Citation |
Score |
| 2024 |
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, et al. Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38456660 DOI: 10.1158/1078-0432.CCR-23-3135 |
0.31 |
|
| 2024 |
Balasooriya ER, Wu Q, Ellis H, Zhen Y, Norden BL, Corcoran RB, Mohan A, Martin E, Franovic A, Tyhonas J, Lardy M, Grandinetti KB, Pelham R, Soroceanu L, Silveira VS, et al. The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38437671 DOI: 10.1158/1078-0432.CCR-23-3588 |
0.302 |
|
| 2024 |
Rubinson DA, Tanaka N, Fece de la Cruz F, Kapner KS, Rosenthal MH, Norden BL, Barnes H, Ehnstrom S, Morales-Giron AA, Brais LK, Lemke CT, Aguirre AJ, Corcoran RB. Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer Discovery. PMID 38236605 DOI: 10.1158/2159-8290.CD-23-1138 |
0.359 |
|
| 2023 |
Varkaris A, Fece de la Cruz F, Martin EE, Norden BL, Chevalier N, Kehlmann AM, Leshchiner I, Barnes H, Ehnstrom S, Stavridi AM, Yuan X, Kim JS, Ellis H, Papatheodoridi A, Gunaydin H, ... ... Corcoran RB, et al. Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discovery. PMID 37916958 DOI: 10.1158/2159-8290.CD-23-0704 |
0.343 |
|
| 2023 |
Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, ... ... Corcoran RB, et al. Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial. Nature Medicine. PMID 36702949 DOI: 10.1038/s41591-022-02181-8 |
0.332 |
|
| 2023 |
Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, ... ... Corcoran RB, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. PMID 36634707 DOI: 10.1038/s41586-023-05704-6 |
0.301 |
|
| 2021 |
Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, ... ... Corcoran RB, et al. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery. PMID 33926920 DOI: 10.1158/2159-8290.CD-20-1669 |
0.3 |
|
| 2021 |
Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, ... ... Corcoran RB, et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discovery. PMID 33824136 DOI: 10.1158/2159-8290.CD-21-0365 |
0.356 |
|
| 2020 |
Chaudhary S, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, et al. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. The Oncologist. PMID 32820577 DOI: 10.1634/Theoncologist.2020-0274 |
0.408 |
|
| 2020 |
Lin JJ, Langenbucher A, Gupta P, Yoda S, Fetter IJ, Rooney M, Do A, Kem M, Chang KP, Oh AY, Chin E, Juric D, Corcoran RB, Dagogo-Jack I, Gainor JF, et al. Small cell transformation of fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology. 4: 21. PMID 32802958 DOI: 10.1038/s41698-020-0127-9 |
0.308 |
|
| 2020 |
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nature Reviews. Clinical Oncology. PMID 32632268 DOI: 10.1038/S41571-020-0392-0 |
0.401 |
|
| 2020 |
Jalili P, Bowen D, Langenbucher A, Park S, Aguirre K, Corcoran RB, Fleischman AG, Lawrence MS, Zou L, Buisson R. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nature Communications. 11: 2971. PMID 32532990 DOI: 10.1038/S41467-020-16802-8 |
0.406 |
|
| 2020 |
Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: e292-e308. PMID 32453634 DOI: 10.1200/EDBK_280845 |
0.345 |
|
| 2020 |
Corcoran RB, Grothey A. Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction? Jama Oncology. PMID 32379270 DOI: 10.1001/Jamaoncol.2020.0504 |
0.396 |
|
| 2020 |
Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, ... ... Corcoran RB, et al. BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32047001 DOI: 10.1158/1078-0432.Ccr-19-3579 |
0.465 |
|
| 2020 |
Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, ... ... Corcoran RB, et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology. PMID 32042168 DOI: 10.1038/S41587-019-0404-8 |
0.355 |
|
| 2020 |
Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, ... ... Corcoran RB, et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31941831 DOI: 10.1158/1078-0432.Ccr-19-3467 |
0.393 |
|
| 2020 |
Parikh AR, Fish M, Van Seventer EE, Fosbenner K, Kanter K, Allen JN, Clark JW, Giantonio B, Weekes CD, Klempner SJ, Franses JW, Roeland E, Goyal L, Wo JY, Hong TS, ... ... Corcoran RB, et al. The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer. Journal of Clinical Oncology. 38: 833-833. DOI: 10.1200/Jco.2020.38.4_Suppl.833 |
0.336 |
|
| 2020 |
Bitterman DS, Price KS, Van Seventer EE, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Eyler CE, Wo JY, Hong TS, Nipp RD, Roeland E, Murphy JE, Corcoran RB, Weekes CD, et al. Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients. Journal of Clinical Oncology. 38: 753-753. DOI: 10.1200/Jco.2020.38.4_Suppl.753 |
0.377 |
|
| 2020 |
Hong TS, Goyal L, Parikh AR, Yeap BY, Ulysse CA, Drapek LC, Allen JN, Clark JW, Christopher B, Bolton C, Ryan DP, Corcoran RB, Meyerhardt JA, Wo JY, Zhu AX. A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy. Journal of Clinical Oncology. 38: 547-547. DOI: 10.1200/Jco.2020.38.4_Suppl.547 |
0.347 |
|
| 2020 |
Bitterman DS, Niemierko A, Van Seventer EE, Kim DW, Qadan M, Blaszkowsky LS, Clark JW, Zhu AX, Goyal L, Keane F, Eyler CE, Parikh AR, Corcoran RB, Wo JY, Hong TS. Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors. Journal of Clinical Oncology. 38: 515-515. DOI: 10.1200/Jco.2020.38.4_Suppl.515 |
0.387 |
|
| 2020 |
Parikh AR, Rajurkar M, Van Seventer EE, Gemma AJ, Allen JN, Blaszkowsky LS, Clark JW, Goyal L, Hong TS, Wo JY, Corcoran RB, Solovyov A, Greenbaum B, Szabolcs A, Tai EC, et al. Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 38: 149-149. DOI: 10.1200/Jco.2020.38.4_Suppl.149 |
0.372 |
|
| 2020 |
Ryan MB, Cruz FFdl, Ahronian LG, Phat S, Myers DT, Shahzade HA, Hong C, Corcoran RB. Abstract B50: ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B50 |
0.498 |
|
| 2020 |
Corcoran R, Giannakis M, Allen J, Chen J, Pelka K, Chao S, Meyerhardt J, Enzinger A, Enzinger P, McCleary N, Yugelun M, Abrams T, Kanter K, Seventer EV, Bradford W, et al. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients Annals of Oncology. 31. DOI: 10.1016/J.Annonc.2020.04.041 |
0.388 |
|
| 2019 |
Parikh A, Clark J, Wo J, Yeap B, Allen J, Blaszkowsky L, Ryan D, Giantonio B, Weekes C, Zhu A, Van Seventer E, Ly L, Matlack L, Foreman B, Drapek L, ... ... Corcoran R, et al. Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv128. PMID 32085022 DOI: 10.1093/Annonc/Mdz154.007 |
0.348 |
|
| 2019 |
Mauri G, Kanter K, Fish M, Horick N, Allen J, Blaszkowsky L, Clark J, Ryan D, Nipp R, Giantonio B, Goyal L, Dubois J, Murphy J, Roeland E, Weekes C, ... ... Corcoran R, et al. PARP-ness in metastatic colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv117. PMID 32084989 DOI: 10.1093/Annonc/Mdz156.021 |
0.41 |
|
| 2019 |
Parikh A, Kanter K, Mojtahed A, Schneider J, Van Seventer E, Fish M, Allen J, Blaszkowsky L, Wo J, Clark J, Giantonio B, Goyal L, Hong T, Nipp R, Roeland E, ... ... Corcoran R, et al. Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv112. PMID 32084975 DOI: 10.1093/Annonc/Mdz156.007 |
0.393 |
|
| 2019 |
Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, Hong CB, Corcoran RB. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31776128 DOI: 10.1158/1078-0432.Ccr-19-3523 |
0.371 |
|
| 2019 |
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... ... Corcoran RB, et al. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. PMID 31745334 DOI: 10.1038/S41591-019-0698-6 |
0.381 |
|
| 2019 |
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548343 DOI: 10.1158/1078-0432.Ccr-19-1667 |
0.458 |
|
| 2019 |
Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31515458 DOI: 10.1158/1078-0432.Ccr-19-2004 |
0.423 |
|
| 2019 |
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... ... Corcoran RB, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. 25: 1415-1421. PMID 31501609 DOI: 10.1038/S41591-019-0561-9 |
0.439 |
|
| 2019 |
Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31373349 DOI: 10.1093/Annonc/Mdz227 |
0.355 |
|
| 2019 |
Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31253631 DOI: 10.1158/1078-0432.Ccr-19-0908 |
0.359 |
|
| 2019 |
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, ... ... Corcoran RB, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. Jama Oncology. PMID 31145418 DOI: 10.1001/Jamaoncol.2019.0892 |
0.385 |
|
| 2019 |
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leshchiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, ... ... Corcoran RB, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discovery. PMID 31109923 DOI: 10.1158/2159-8290.Cd-19-0182 |
0.424 |
|
| 2019 |
Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 39: 207-215. PMID 31099678 DOI: 10.1200/EDBK_240839 |
0.31 |
|
| 2019 |
Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, et al. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. The Oncologist. PMID 31040255 DOI: 10.1634/Theoncologist.2019-0034 |
0.439 |
|
| 2019 |
Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discovery. PMID 30770389 DOI: 10.1158/2159-8290.Cd-18-1321 |
0.43 |
|
| 2019 |
Corcoran RB, Chabner BA. Cell-free DNA Analysis in Cancer. The New England Journal of Medicine. 380: 501-502. PMID 30699310 DOI: 10.1056/Nejmc1816154 |
0.347 |
|
| 2019 |
Fece de la Cruz F, Corcoran RB. Methylation in cell-free DNA for early cancer detection. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: 1351-1353. PMID 29668834 DOI: 10.1093/Annonc/Mdy134 |
0.321 |
|
| 2019 |
Kotani D, Mondaca S, Parikh A, Bando H, Van Seventer E, Taniguchi H, Yoshino T, Corcoran RB, Yaeger R, Ebi H. Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer. Journal of Clinical Oncology. 37: 659-659. DOI: 10.1200/Jco.2019.37.4_Suppl.659 |
0.395 |
|
| 2019 |
Raghav KPS, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 37: 604-604. DOI: 10.1200/Jco.2019.37.4_Suppl.604 |
0.416 |
|
| 2019 |
Henry J, Loree JM, Strickler JH, Raghav KPS, Morris VK, Raymond VM, Lanman RB, Yaeger R, Corcoran RB, Overman MJ, Kopetz S. Quantifying the evolution of tumor architecture using serial circulating tumor DNA. Journal of Clinical Oncology. 37: 600-600. DOI: 10.1200/Jco.2019.37.4_Suppl.600 |
0.401 |
|
| 2019 |
McDuff SG, Hardiman K, Parikh AR, Ulintz P, Hazar-Rethinam M, Zheng H, Van Seventer E, Fetter I, Nadres B, Ryan DP, Weekes CD, Clark JW, Cusack JC, Goyal L, Zhu AX, ... ... Corcoran RB, et al. Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC). Journal of Clinical Oncology. 37: 562-562. DOI: 10.1200/Jco.2019.37.4_Suppl.562 |
0.339 |
|
| 2019 |
Parikh A, Wo JY, Ryan DP, Clark JW, Nipp RD, Blaszkowsky LS, Weekes CD, Van Seventer E, Ly L, Foreman B, Corcoran RB, Hong TS. A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 37: 391-391. DOI: 10.1200/Jco.2019.37.4_Suppl.391 |
0.32 |
|
| 2019 |
Wo JY, Clark JW, Allen JN, Blaszkowsky LS, Keane F, Drapek LC, Ryan DP, Corcoran RB, Roeland E, Parikh AR, Khandekar MJ, Heist RS, Morse C, Yeap BY, Ulysse CA, et al. A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results. Journal of Clinical Oncology. 37: 4057-4057. DOI: 10.1200/Jco.2019.37.15_Suppl.4057 |
0.317 |
|
| 2019 |
Parikh AR, Van Seventer EE, Boland GM, Hartwig A, Jaimovich A, Raymond VM, Talasaz A, Corcoran RB. A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC). Journal of Clinical Oncology. 37: 3602-3602. DOI: 10.1200/Jco.2019.37.15_Suppl.3602 |
0.332 |
|
| 2019 |
Fish M, Kanter K, Mauri G, Horick N, Allen JN, Blaszkowsky LS, Clark JW, Ryan DP, Nipp RD, Giantonio BJ, Goyal L, Murphy JE, Roeland E, Weekes CD, Wo JY, ... ... Corcoran RB, et al. Aggressiveness of care and overall survival in young metastatic colorectal cancer patients. Journal of Clinical Oncology. 37: 3563-3563. DOI: 10.1200/Jco.2019.37.15_Suppl.3563 |
0.349 |
|
| 2019 |
Parikh AR, Clark JW, Wo JY, Yeap BY, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio BJ, Weekes CD, Zhu AX, Van Seventer EE, Matlack L, Foreman B, Ly L, Drapek LC, ... ... Corcoran RB, et al. A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). Journal of Clinical Oncology. 37: 3514-3514. DOI: 10.1200/Jco.2019.37.15_Suppl.3514 |
0.322 |
|
| 2019 |
Hartwig A, Artieri C, Jaimovich A, Van Seventer EE, Parikh AR, Corcoran RB, Baca A, Talasaz A. Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer. Journal of Clinical Oncology. 37: 3057-3057. DOI: 10.1200/Jco.2019.37.15_Suppl.3057 |
0.393 |
|
| 2019 |
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin L, Seventer EEV, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... ... Corcoran RB, et al. Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-257 |
0.389 |
|
| 2019 |
Maruvka YE, Frazer R, Grimsby J, Cibulskis C, Adalsteinsson V, Corcoran R, Getz G. Abstract 2677: MSIClass–Identification and classification of microsatellite unstable using cell-free DNA from ultra-low-pass sequencing Cancer Research. 79: 2677-2677. DOI: 10.1158/1538-7445.Am2019-2677 |
0.365 |
|
| 2019 |
Ryan MB, Cruz FFdl, Phat S, Myers DT, Shahzade HA, Hong CB, Corcoran RB. Abstract A129: Vertical inhibition overcomes adaptive resistance to KRASG12C inhibition Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A129 |
0.44 |
|
| 2019 |
Maruvka YE, Frazer R, Grimsby J, Seventer EEV, Cibulskis C, Adalsteinsson V, Corcoran R, Getz G. Abstract A094: MSIClass - Identification and classification of microsatellite unstable tumors using cell-free DNA from ultra low pass sequencing Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A094 |
0.363 |
|
| 2019 |
Corcoran R, Do K, Cleary J, Parikh A, Yeku O, Weekes C, Veneris J, Ahronian L, Mauri G, Van Seventer E, Fetter I, Gurski J, Matulonis U, Juric D, Flaherty K, et al. Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours Annals of Oncology. 30: v164. DOI: 10.1093/Annonc/Mdz244.009 |
0.394 |
|
| 2019 |
Parikh A, Seventer EV, Boland G, Hartwig A, Jaimovich A, Raymond V, Talasaz A, Corcoran R. Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz154.015 |
0.407 |
|
| 2019 |
Wo JY, Clark JW, Roeland E, Parikh AS, Corcoran R, Ryan DP, Drapek LC, Keane FK, Khandekar MJ, Baglini C, Allen JN, Heist R, Lanuti M, Morse CR, Seventer EV, et al. A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.554 |
0.325 |
|
| 2018 |
Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, ... ... Corcoran RB, et al. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30462160 DOI: 10.1093/Annonc/Mdy509 |
0.391 |
|
| 2018 |
Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. The New England Journal of Medicine. 379: 1754-1765. PMID 30380390 DOI: 10.1097/01.Ogx.0000554379.46945.9E |
0.393 |
|
| 2018 |
Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. The Oncologist. PMID 30373904 DOI: 10.1634/Theoncologist.2018-0152 |
0.352 |
|
| 2018 |
Siravegna G, Corcoran RB. Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast. Cancer Discovery. 8: 1213-1215. PMID 30279194 DOI: 10.1158/2159-8290.Cd-18-0952 |
0.42 |
|
| 2018 |
Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nature Reviews. Clinical Oncology. PMID 30275515 DOI: 10.1038/S41571-018-0105-0 |
0.342 |
|
| 2018 |
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, ... ... Corcoran RB, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. PMID 29903880 DOI: 10.1158/2159-8290.Cd-18-0275 |
0.371 |
|
| 2018 |
Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, et al. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine. PMID 29771009 DOI: 10.1002/Cam4.1558 |
0.416 |
|
| 2018 |
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 7: e1423172. PMID 29721378 DOI: 10.1080/2162402X.2017.1423172 |
0.372 |
|
| 2018 |
Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery. PMID 29431699 DOI: 10.1158/2159-8290.Cd-17-1226 |
0.449 |
|
| 2018 |
Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, ... ... Corcoran RB, et al. Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer. Cancer Discovery. PMID 29431697 DOI: 10.1158/2159-8290.Cd-17-1227 |
0.466 |
|
| 2018 |
Hong TS, Hwang KL, Clark JW, Lennerz JK, Shui A, Zheng H, Szymonifka J, Corcoran RB, Heist RS, Russo AL, Parikh AR, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, et al. MET-amplification (MET-amp) in relation to aggressive biology in esophagogastric cancer (EGC): An analysis of clinical outcomes of MET-amp vs non-MET-amp EGC. Journal of Clinical Oncology. 36: 74-74. DOI: 10.1200/Jco.2018.36.4_Suppl.74 |
0.44 |
|
| 2018 |
Kamran SC, Lennerz JK, Margolis C, Liu D, Reardon B, Wankowicz SA, Wo JY, Willers H, Corcoran RB, Van Allen EM, Hong TS. Genomic evolution and acquired resistance to preoperative chemoradiation therapy (CRT) in rectal cancer. Journal of Clinical Oncology. 36: 613-613. DOI: 10.1200/Jco.2018.36.4_Suppl.613 |
0.445 |
|
| 2018 |
Mitra D, Shih HA, Oh K, Brastianos P, Wo JY, Curry W, Clark JW, Parikh A, Corcoran RB, Ryan DP, Lennerz JK, Hong TS. HER2 positivity in brain metastases from gastrointestinal primary malignancies. Journal of Clinical Oncology. 36: 61-61. DOI: 10.1200/Jco.2018.36.4_Suppl.61 |
0.431 |
|
| 2018 |
Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Catenacci DV, Chao J, Fakih M, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy. Journal of Clinical Oncology. 36: 43-43. DOI: 10.1200/Jco.2018.36.4_Suppl.43 |
0.417 |
|
| 2018 |
McDuff S, Parikh AR, Hazar-Rethinam M, Zheng H, Van Seventer E, Nadres B, Ryan DP, Weekes CD, Clark JW, Fernandez-del Castillo C, Ferrone C, Lillemoe KD, Murphy JE, Goyal L, Zhu AX, ... ... Corcoran RB, et al. Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC). Journal of Clinical Oncology. 36: 272-272. DOI: 10.1200/Jco.2018.36.4_Suppl.272 |
0.313 |
|
| 2018 |
Clifton K, Raymond VM, Dasari A, Raghav KPS, Parseghian CM, Pereira AAL, Loree JM, Yaeger R, Strickler JH, Corcoran RB, Lanman RB, Kopetz S, Morris VK. Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay. Journal of Clinical Oncology. 36: 3507-3507. DOI: 10.1200/Jco.2018.36.15_Suppl.3507 |
0.395 |
|
| 2018 |
Medford A, Niemierko A, Moy B, Spring L, Malvarosa G, Younger J, Lanman RB, Nagy RJ, Corcoran RB, Isakoff SJ, Ellisen LW, Juric D, Bardia A. Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes. Journal of Clinical Oncology. 36: 1021-1021. DOI: 10.1200/Jco.2018.36.15_Suppl.1021 |
0.433 |
|
| 2018 |
Shi A, Cintolo-Gonzalez JA, Chien I, Frederick DT, Alpatov R, Michaud W, Plana D, Panka D, Corcoran R, Flaherty K, Sullivan R, Kellis M, Boland G. Abstract B25: Exosomal transcriptomic signatures tracks and predicts response to checkpoint blockade immunotherapy Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B25 |
0.357 |
|
| 2018 |
Corcoran RB. Abstract IA15: Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-Ia15 |
0.513 |
|
| 2018 |
Goyal L, Liu LY, Lennerz JK, Harding JJ, Huang J, Winkler R, Hiroshi H, Ting DT, Juric D, Corcoran RB, El-Bardeesy N, Zhu AX. Abstract LB-092: TAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-092 |
0.464 |
|
| 2018 |
Shi A, Kasumova G, Chien I, Cintolo-Gonzalez J, Frederick DT, Alpatov R, Michaud WA, Plana D, Corcoran R, Flaherty K, Sullivan R, Kellis M, Boland G. Abstract 4282: Deconvolution of plasma-derived exosomes for tracking and prediction of immunotherapy across multiple tissues Cancer Research. 78: 4282-4282. DOI: 10.1158/1538-7445.Am2018-4282 |
0.342 |
|
| 2018 |
Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Seventer EEV, ... ... Corcoran RB, et al. Abstract LB-A34: Modeling convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAF-mutant colorectal cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A34 |
0.483 |
|
| 2018 |
Goyal L, Kelley RK, Kiedrowski L, Catenacci D, Mody K, Shroff R, Parikh A, Reyes S, Maurer JR, Corcoran RB, Fanta P, Cusnir M, Nagy B, Lanman R, Morse M, et al. Abstract A183: Blood-based genomic profiling of cell-free tumor DNA (ctDNA) in patients with biliary tract cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A183 |
0.495 |
|
| 2018 |
McDuff S, Parikh A, Hazar-Rethinam M, Zheng H, Van Seventer E, Nadres B, Lennerz J, Ryan D, Weekes C, Clark J, Casti CF, Ferrone C, Lillemoe K, Goyal L, Zhu A, ... ... Corcoran R, et al. Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S134. DOI: 10.1016/J.Ijrobp.2018.06.330 |
0.355 |
|
| 2017 |
Parikh A, Goyal L, Hazar-Rethinam M, Siravegna G, Blaszkowsky L, Russo M, Van Seventer E, Nadres B, Shahzade H, Clark J, Allen J, John IA, Ryan DP, Murphy J, Bardelli A, ... ... Corcoran R, et al. Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii137. PMID 32135760 DOI: 10.1093/Annonc/Mdx262 |
0.406 |
|
| 2017 |
Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, ... Corcoran RB, et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discovery. PMID 29196463 DOI: 10.1158/2159-8290.Cd-17-1009 |
0.472 |
|
| 2017 |
Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, ... ... Corcoran RB, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications. 8: 1136. PMID 29070816 DOI: 10.1038/S41467-017-01062-W |
0.396 |
|
| 2017 |
Parikh AR, Corcoran RB. Fast-TRKing Drug Development for Rare Molecular Targets. Cancer Discovery. 7: 934-936. PMID 28864638 DOI: 10.1158/2159-8290.Cd-17-0704 |
0.394 |
|
| 2017 |
Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, Gainor J, Azzoli CG, Temel J, Mino-Kenudson M, Dias-Santagata D, ... Corcoran R, et al. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. International Journal of Radiation Oncology, Biology, Physics. 98: 220. PMID 28586967 DOI: 10.1016/J.Ijrobp.2017.01.037 |
0.388 |
|
| 2017 |
Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Medicine. 9: 37. PMID 28431544 DOI: 10.1186/S13073-017-0431-3 |
0.46 |
|
| 2017 |
Strickler JH, Banks KC, Nagy RJ, Lanman RB, Talasaz A, Corcoran RB, Kopetz S. Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC). Journal of Clinical Oncology. 35: 584-584. DOI: 10.1200/Jco.2017.35.4_Suppl.584 |
0.422 |
|
| 2017 |
Corcoran RB. Abstract IA23: Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Ia23 |
0.513 |
|
| 2017 |
Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Mussolin B, Reyes S, Furet P, Iafrate AJ, Getz G, Porta DG, Tiedt R, ... ... Corcoran RB, et al. Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients Cancer Research. 77: 4114-4114. DOI: 10.1158/1538-7445.Am2017-4114 |
0.495 |
|
| 2017 |
Ahronian LG, Misale S, Godfrey JT, Nishimura K, Chen L, Engelman JA, Corcoran RB. Abstract 101: Adaptive feedback reactivates MAPK signaling in KRAS-mutant cancers with inhibition of MEK, but not ERK Cancer Research. 77: 101-101. DOI: 10.1158/1538-7445.Am2017-101 |
0.454 |
|
| 2017 |
Piotrowska Z, Stirling K, Heist R, Mooradian M, Rizzo C, Digumarthy S, Lanuti M, Fintelmann F, Lennes I, Farago A, Gainor J, Azzoli C, Temel J, Mino-Kenudson M, Dias-Santagata D, ... Corcoran R, et al. OA 07.05 Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms Journal of Thoracic Oncology. 12: S1762. DOI: 10.1016/J.Jtho.2017.09.364 |
0.346 |
|
| 2017 |
Kamran S, Lennerz J, Reardon B, Mullane S, Wo J, Willers H, Corcoran R, Van Allen E, Hong T. Genomic Evolution and Acquired Resistance to Pre-Operative Chemoradiation Therapy in Locally Advanced Rectal Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S22-S23. DOI: 10.1016/J.Ijrobp.2017.06.065 |
0.366 |
|
| 2016 |
Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, ... ... Corcoran RB, et al. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery. PMID 28034880 DOI: 10.1158/2159-8290.Cd-16-1000 |
0.485 |
|
| 2016 |
Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. PMID 27338794 DOI: 10.1038/Nature18600 |
0.468 |
|
| 2016 |
Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, ... ... Corcoran RB, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Research. PMID 27312529 DOI: 10.1158/0008-5472.Can-16-0396 |
0.475 |
|
| 2016 |
Ahronian LG, Corcoran RB. Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Molecular & Cellular Oncology. 3: e1048405. PMID 27308562 DOI: 10.1080/23723556.2015.1048405 |
0.507 |
|
| 2016 |
Bernstein BE, Gray N, Boyd MR, Corcoran RB, Stone RM, Armand P, Sykes DB, Gopal R, Gala MK, Liu D, Tothova Z, Nodelman O, Maus MV, Wu CJ. Chabner Colloquium: Answering the Big Questions in Cancer Research & 2016 STO Annual Meeting Oncologist. 21. DOI: 10.1634/Theoncologist.2016-Ma-1 |
0.328 |
|
| 2016 |
Kamran SC, Clark JW, Borger DR, Szymonifka J, Kwak EL, Blaszkowsky LS, Murphy JE, Goyal L, Allen JN, Wo JY, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Clinical correlation with codon-specific mutations in metastatic colorectal cancer. Journal of Clinical Oncology. 34: 3596-3596. DOI: 10.1200/Jco.2016.34.15_Suppl.3596 |
0.425 |
|
| 2016 |
Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, ... ... Corcoran RB, et al. Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer Cancer Research. 76: 878-878. DOI: 10.1158/1538-7445.Am2016-878 |
0.521 |
|
| 2016 |
Corcoran R, André T, Yoshino T, Bendell J, Atreya C, Schellens J, Ducreux M, McRee A, Siena S, Middleton G, Gordon M, Humblet Y, Muro K, Elez E, Yaeger R, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 27: vi150. DOI: 10.1093/Annonc/Mdw370.04 |
0.438 |
|
| 2016 |
Parikh A, Kwak E, Goyal L, Blaszkowsky L, Hazar-Rethinam M, Siravegna G, Russo M, Van Seventer E, Nadres B, Shahzade H, Clark J, Allen J, Iafrate A, Bardellli A, Ryan D, ... ... Corcoran R, et al. A systematic liquid biopsy program identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients European Journal of Cancer. 69: S3. DOI: 10.1016/S0959-8049(16)32610-7 |
0.378 |
|
| 2015 |
Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology. 6: 650-9. PMID 26697198 DOI: 10.3978/J.Issn.2078-6891.2015.076 |
0.456 |
|
| 2015 |
Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, ... ... Corcoran RB, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discovery. PMID 26644315 DOI: 10.1158/2159-8290.Cd-15-1283 |
0.474 |
|
| 2015 |
Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discovery. PMID 26432108 DOI: 10.1158/2159-8290.Cd-15-0748 |
0.485 |
|
| 2015 |
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26392102 DOI: 10.1200/Jco.2015.63.2471 |
0.446 |
|
| 2015 |
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, ... ... Corcoran RB, et al. Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine. 21: 827. PMID 26151329 DOI: 10.1038/nm0715-827b |
0.325 |
|
| 2015 |
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, ... ... Corcoran RB, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine. PMID 26030179 DOI: 10.1038/Nm.3870 |
0.455 |
|
| 2015 |
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, ... ... Corcoran RB, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.Cd-14-1518 |
0.53 |
|
| 2015 |
Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 682-5. PMID 25584005 DOI: 10.1200/Jco.2014.58.9325 |
0.435 |
|
| 2015 |
Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 396-404. PMID 25348516 DOI: 10.1158/1078-0432.Ccr-14-1591 |
0.395 |
|
| 2015 |
Kwak EL, Lennerz JK, Szymonifka J, Corcoran RB, Clark JW, Russo AL, Borger DR, Blaszkowsky LS, Dias LE, Faris JE, Murphy JE, Fidias P, Lennes IT, Azzoli CG, Gainor JF, et al. Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. Journal of Clinical Oncology. 33: 4043-4043. DOI: 10.1200/Jco.2015.33.15_Suppl.4043 |
0.408 |
|
| 2015 |
Siravegna G, Mussolin B, Buscarino M, Corti G, Crisafulli G, Ponzetti A, Cremolini C, Lamba S, Avallone A, Rospo G, Veronese S, Budillon A, Montagut C, Racca P, Corcoran RB, et al. Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. Journal of Clinical Oncology. 33: 11073-11073. DOI: 10.1200/Jco.2015.33.15_Suppl.11073 |
0.403 |
|
| 2015 |
Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, McRee AJ, O'Dwyer PJ, Muro K, Tabernero J, van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, ... ... Corcoran RB, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: 103-103. DOI: 10.1200/Jco.2015.33.15_Suppl.103 |
0.444 |
|
| 2015 |
Corcoran RB, Ahronian LG, Allen EV, Coffee EM, Wagle N, Kwak EL, Faris JE, Iafrate AJ, Garraway LA, Engelman JA. Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng04 |
0.512 |
|
| 2015 |
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Corcoran RB, Ponzetti A, Budillon A, Racca P, Marsoni S, Nicolantonio FD, Loupakis F, Siena S, Bianchi AS, et al. Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients Cancer Research. 75: 616-616. DOI: 10.1158/1538-7445.Am2015-616 |
0.428 |
|
| 2015 |
Siravegna G, Russo M, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, ... ... Corcoran RB, et al. Abstract PR01: Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Pr01 |
0.513 |
|
| 2015 |
Van Cutsem E, Atreya C, André T, Bendell J, Schellens J, Gordon M, McRee A, Yoshino T, Muro K, ODwyer P, Tabernero J, Middleton G, Ducreux M, van Geel R, Sidhu R, ... ... Corcoran R, et al. LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 26: iv119. DOI: 10.1093/Annonc/Mdv262.07 |
0.428 |
|
| 2014 |
Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, ... ... Corcoran RB, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discovery. 4: 452-65. PMID 24444711 DOI: 10.1158/2159-8290.Cd-13-0646 |
0.41 |
|
| 2014 |
Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, ... Corcoran RB, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery. 4: 42-52. PMID 24163374 DOI: 10.1158/2159-8290.Cd-13-0315 |
0.493 |
|
| 2014 |
Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan D, Kurzrock R, Sun P, Cunningham EA, Orford KW, Motwani M, Bai Y, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. Journal of Clinical Oncology. 32: 3517-3517. DOI: 10.1200/Jco.2014.32.15_Suppl.3517 |
0.444 |
|
| 2014 |
Bendell JC, Atreya CE, André T, Tabernero J, Gordon MS, Bernards R, Van Cutsem E, Tejpar S, Sidhu R, Go WY, Allred A, Motwani M, Suttle BB, Wu Y, Hoos A, ... ... Corcoran RB, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). Journal of Clinical Oncology. 32: 3515-3515. DOI: 10.1200/Jco.2014.32.15_Suppl.3515 |
0.443 |
|
| 2014 |
Coffee EM, Corcoran RB, Engelman JA. Abstract 3135: Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition Cancer Research. 74: 3135-3135. DOI: 10.1158/1538-7445.Am2014-3135 |
0.464 |
|
| 2014 |
Corcoran R, Coffee E, van Allen E, Ahronian L, Wagle N, Kwak E, Faris J, Iafrate A, Garraway L, Engelman J. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations European Journal of Cancer. 50: 141. DOI: 10.1016/S0959-8049(14)70554-4 |
0.481 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98. PMID 23903755 DOI: 10.1126/Scitranslmed.3005753 |
0.412 |
|
| 2013 |
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 23: 121-8. PMID 23245996 DOI: 10.1016/J.Ccr.2012.11.007 |
0.479 |
|
| 2013 |
Corcoran RB, Ebi H, Ryan DP, Meyerhardt JA, Engelman JA. Relationship of EGFR-independent activation of PI3K in KRAS wild-type colorectal cancers and cetuximab resistance. Journal of Clinical Oncology. 31: 385-385. DOI: 10.1200/Jco.2013.31.4_Suppl.385 |
0.504 |
|
| 2013 |
Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan DP, Kurzrock R, Atreya CE, Luan J, Sun P, Schaeffer M, Motwani M, Bleam MR, et al. Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). Journal of Clinical Oncology. 31: 3507-3507. DOI: 10.1200/Jco.2013.31.15_Suppl.3507 |
0.371 |
|
| 2013 |
Corcoran RB. Abstract SY10-01: Strategies to overcome resistance to MAPK inhibition. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy10-01 |
0.535 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Winokur D, Piris A, Nazarian RM, Brown RD, Godfrey JT, Mino-Kenudson M, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. Cancer Research. 73: 4568-4568. DOI: 10.1158/1538-7445.Am2013-4568 |
0.472 |
|
| 2013 |
Coffee EM, Faber AC, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, J E, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, ... Corcoran RB, et al. Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C263 |
0.482 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C137 |
0.492 |
|
| 2013 |
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Shioda T, Dias-Santagata D, Singh A, et al. Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr09 |
0.499 |
|
| 2013 |
Corcoran R, Godfrey J, Engelman J. Different Subsets of Braf Mutant Colorectal Cancers Exhibit Egfr-Dependent and Independent Resistance to Raf Inhibitor Therapy Annals of Oncology. 24: iv25. DOI: 10.1093/Annonc/Mdt202.3 |
0.472 |
|
| 2013 |
Corcoran R, Rothenberg M, Piris A, Nazarian R, Maheswaran S, Settleman J, Wargo J, Flaherty K, Haber D, Engelman J. MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients European Journal of Cancer. 49: S12. DOI: 10.1016/S0959-8049(13)70119-9 |
0.35 |
|
| 2012 |
Corcoran RB, Ebi H, Ryan DP, Meyerhardt JA, Engelman JA. Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 462. PMID 27983029 DOI: 10.1200/Jco.2012.30.4_Suppl.462 |
0.493 |
|
| 2012 |
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery. 2: 227-35. PMID 22448344 DOI: 10.1158/2159-8290.Cd-11-0341 |
0.475 |
|
| 2012 |
Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel K, Kopetz S, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). Journal of Clinical Oncology. 30: 3528-3528. DOI: 10.1200/Jco.2012.30.15_Suppl.3528 |
0.45 |
|
| 2012 |
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Dias-Santagata D, Pelle PD, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, et al. Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-350 |
0.513 |
|
| 2012 |
Corcoran RB, Cheng KA, Wong K, Engelman JA. Abstract 875: Markedin vivoefficacy of combined BCLXL and MEK inhibition in KRAS mutant cancers revealed by a pooled shRNA-drug screen for genes that are “synthetically lethal” with MEK inhibitors Cancer Research. 72: 875-875. DOI: 10.1158/1538-7445.Am2012-875 |
0.508 |
|
| 2012 |
Rothenberg SM, Wargo J, Juric D, Corcoran RB, Winokur D, Flaherty KT, Baselga J, Maheswaran S, Engelman JA, Haber DA. Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy Cancer Research. 72: 2446-2446. DOI: 10.1158/1538-7445.Am2012-2446 |
0.467 |
|
| 2012 |
Corcoran RB, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Pelle PD, et al. Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling Clinical Cancer Research. 18: PR8-PR8. DOI: 10.1158/1078-0432.MECHRES-PR8 |
0.375 |
|
| 2012 |
Corcoran R, Cheng K, Hata A, Faber A, Singh A, Settleman J, Benes C, Mino-Kenudson M, Wong K, Engelman J. 149 Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models European Journal of Cancer. 48: 46. DOI: 10.1016/S0959-8049(12)71947-0 |
0.422 |
|
| 2011 |
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 1: 352-65. PMID 22145099 DOI: 10.1158/2159-8290.Cd-11-0106 |
0.459 |
|
| 2011 |
Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of Clinical Investigation. 121: 4311-21. PMID 21985784 DOI: 10.1172/Jci57909 |
0.483 |
|
| 2011 |
Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Research. 71: 5020-9. PMID 21586612 DOI: 10.1158/0008-5472.Can-11-0908 |
0.399 |
|
| 2011 |
Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2: 336-46. PMID 21505228 DOI: 10.18632/Oncotarget.262 |
0.443 |
|
| 2011 |
Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Cantley LC, Wong K, Engelman JA. Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers Cancer Research. 71: 956-956. DOI: 10.1158/1538-7445.Am2011-956 |
0.5 |
|
| 2010 |
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling. 3: ra84. PMID 21098728 DOI: 10.1126/Scisignal.2001148 |
0.472 |
|
| 2010 |
Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1075-83. PMID 20085938 DOI: 10.1200/Jco.2009.25.3641 |
0.478 |
|
| 2009 |
Rohatgi R, Milenkovic L, Corcoran RB, Scott MP. Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proceedings of the National Academy of Sciences of the United States of America. 106: 3196-201. PMID 19218434 DOI: 10.1073/Pnas.0813373106 |
0.669 |
|
| 2009 |
Scott M, Rohatgi R, Milenkovic L, Lee E, Corcoran R, Barakat M, Humke E. S02-04 Communicating with Hedgehogs: Signaling in development and disease Mechanisms of Development. 126: S26-S27. DOI: 10.1016/J.Mod.2009.06.1065 |
0.676 |
|
| 2008 |
Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Research. 68: 8788-95. PMID 18974121 DOI: 10.1158/0008-5472.Can-08-2135 |
0.654 |
|
| 2006 |
Corcoran RB, Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 8408-13. PMID 16707575 DOI: 10.1073/Pnas.0602852103 |
0.531 |
|
| 2001 |
Corcoran RB, Scott MP. A mouse model for medulloblastoma and basal cell nevus syndrome. Journal of Neuro-Oncology. 53: 307-18. PMID 11718263 DOI: 10.1023/A:1012260318979 |
0.535 |
|
| Show low-probability matches. |